Michelle Arbesman

Michelle Arbesman

Auto-generated profile, based on publicly available information

Michelle Arbesman

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAlan Shen
Alan Shen
MAMichelle Arbesman
Michelle Arbesman
RLRoshan Lodha
Roshan Lodha
PRPatricia Rayman
Patricia Rayman
BBBrandon Bungo
Brandon Bungo
Pauline FunchainPauline Funchain
Pauline Funchain
Purpose: Malignant melanoma represents the most lethal skin cancer with germline predispositions thought to comprise 10% to 15% of all melanoma cases. No studies to date examine the immunologic features that may differentiate survival differences between germline pathogenic variant (gPV)–positive patients with melanoma from gPV-negative patients with melanoma. Experimental Design: Adult patients with melanoma and clinical characteristics suggesting hereditary predisposition to cancer were prospectively recruited to undergo germline testing and flow cytometric analysis of peripheral immune suppressor cells. Results: In this cohort, gPV-positive patients (n = 72) had a significantly improved melanoma-specific survival (MSS) compared with gPV-negative patients (n = 411; HRadj, 0.32; 95% CI, 0.13–0.82; P = 0.01). These survival improvements among gPV-positive patients were most apparent among cutaneous melanoma subtypes (HRadj, 0.12; 95% CI, 0.016–0.86; P = 0.03) and numerically improved in later-stage (IIB–IV) patients (HRadj, 0.34; 95% CI, 0.10–1.11; P = 0.06). Further, gPV-positive patients had a significantly lower level of total circulating PMN-MDSC compared with gPV-negative patients (P = 0.01), which was most apparent in those diagnosed with later stages (IIB–IV) of melanoma (P = 0.009). Finally, a significant upregulation of inflammatory transcriptome signatures in later-stage gPV-positive patients (n = 21) was observed in comparison with gPV-negative patients (n = 173) in the cutaneous melanoma cohort (SKCM) of The Cancer Genome Atlas (TCGA). Conclusions: gPV-positive patients with melanoma exhibit improved MSS in addition to reduced peripheral PMN-MDSC and an enhanced inflammatory microenvironment.

1 February 2024
Verified
Other
Open access
ASAlan Shen
Alan Shen
MAMichelle Arbesman
Michelle Arbesman
RLRoshan Lodha
Roshan Lodha
PRPatricia Rayman
Patricia Rayman
BBBrandon Bungo
Brandon Bungo
Pauline FunchainPauline Funchain
Pauline Funchain
Multivariable linear regression on PMN-MDSC counts.


1 February 2024
Verified
Other
Open access
PDF file
ASAlan Shen
Alan Shen
MAMichelle Arbesman
Michelle Arbesman
RLRoshan Lodha
Roshan Lodha
PRPatricia Rayman
Patricia Rayman
BBBrandon Bungo
Brandon Bungo
Pauline FunchainPauline Funchain
Pauline Funchain
MSS and PMN-MDSC differences by known and putative melanoma variants.

1 February 2024
Verified
Other
Open access
ASAlan Shen
Alan Shen
MAMichelle Arbesman
Michelle Arbesman
RLRoshan Lodha
Roshan Lodha
PRPatricia Rayman
Patricia Rayman
BBBrandon Bungo
Brandon Bungo
Pauline FunchainPauline Funchain
Pauline Funchain
GPV categories broken up by HRD, Non-HRD, and MMR.

1 February 2024
Verified
Other
Open access
PDF file
ASAlan Shen
Alan Shen
MAMichelle Arbesman
Michelle Arbesman
RLRoshan Lodha
Roshan Lodha
PRPatricia Rayman
Patricia Rayman
BBBrandon Bungo
Brandon Bungo
Pauline FunchainPauline Funchain
Pauline Funchain
MSS and PMN-MDSC differences by HRD and Non-HRD status.